All Publications

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.

Liu C. et al, (2024), Nature communications, 15

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.

Zhou D. et al, (2024), Nature communications, 15

Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.

Wei J. et al, (2024), Nature communications, 15

Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.

Keelapang P. et al, (2023), Journal of virology, 97

The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency

Huhn A. et al, (2023)

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

Hornsby H. et al, (2023), Nature Communications, 14

Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody.

Keelapang P. et al, (2023), Microbiology spectrum

Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Thursz M. et al, (2023), The Journal of general virology, 104

Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.

Thursz M. et al, (2023), The Journal of general virology, 104

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Ragonnet-Cronin M. et al, (2023), Nat Commun, 14

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Chenthamarakshan V. et al, (2023), Science advances, 9

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.

Buckell J. et al, (2023), Scientific reports, 13

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.

Wei J. et al, (2023), Nature communications, 14

Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2

Stuart D. et al, (2023)

Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses

Hornsby H. et al, (2023)

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

Wei J. et al, (2022), Nature Communications, 13

Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study

Moore S. et al, (2022)

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Flaxman A. et al, (2021)

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Adams ER. et al, (2020), Wellcome Open Research, 5, 139 - 139

Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.

Fernandez E. et al, (2020), Nature immunology

Cookies on this website

All Publications